BACKGROUND: Recent studies suggested an improved overall survival (OS) for BRCA2- versus BRCA1-associated epithelial ovarian cancer (EOC), whereas the impact of chemotherapy is not yet clear. In a nationwide cohort, we examined the results of primary treatment, progression-free survival (PFS), treatment-free interval (TFI), and OS of BRCA1 versus BRCA2 EOC patients. METHODS: Two hundred and forty-five BRCA1- and 99 BRCA2-associated EOC patients were identified through all Dutch university hospitals. Analyses were carried out with the Pearson's Chi-square test, Kaplan-Meier, and Cox regression methods. RESULTS: BRCA1 patients were younger at EOC diagnosis than BRCA2 patients (51 versus 55 years; P < 0.001), without differences regarding histology, tumor grade, and International Federation of Gynecology and Obstetrics (FIGO) stage. Complete response rates after primary treatment, including chemotherapy, did not differ between BRCA1 (86%) and BRCA2 patients (90%). BRCA1 versus BRCA2 patients had a shorter PFS (median 2.2 versus 3.9 years, respectively; P = 0.006), TFI (median 1.7 versus 2.8 years; P = 0.009), and OS (median 6.0 versus 9.7 years; P = 0.04). Differences could not be explained by age at diagnosis, FIGO stage or type of treatment. CONCLUSIONS: PFS and OS were substantially longer in BRCA2- than in BRCA1-associated EOC patients. While response rates after primary treatment were similarly high in both groups, TFI, as surrogate for chemosensitivity, was significantly longer in BRCA2 patients.
BACKGROUND: Recent studies suggested an improved overall survival (OS) for BRCA2- versus BRCA1-associated epithelial ovarian cancer (EOC), whereas the impact of chemotherapy is not yet clear. In a nationwide cohort, we examined the results of primary treatment, progression-free survival (PFS), treatment-free interval (TFI), and OS of BRCA1 versus BRCA2 EOC patients. METHODS: Two hundred and forty-five BRCA1- and 99 BRCA2-associated EOC patients were identified through all Dutch university hospitals. Analyses were carried out with the Pearson's Chi-square test, Kaplan-Meier, and Cox regression methods. RESULTS:BRCA1patients were younger at EOC diagnosis than BRCA2patients (51 versus 55 years; P < 0.001), without differences regarding histology, tumor grade, and International Federation of Gynecology and Obstetrics (FIGO) stage. Complete response rates after primary treatment, including chemotherapy, did not differ between BRCA1 (86%) and BRCA2patients (90%). BRCA1 versus BRCA2patients had a shorter PFS (median 2.2 versus 3.9 years, respectively; P = 0.006), TFI (median 1.7 versus 2.8 years; P = 0.009), and OS (median 6.0 versus 9.7 years; P = 0.04). Differences could not be explained by age at diagnosis, FIGO stage or type of treatment. CONCLUSIONS: PFS and OS were substantially longer in BRCA2- than in BRCA1-associated EOC patients. While response rates after primary treatment were similarly high in both groups, TFI, as surrogate for chemosensitivity, was significantly longer in BRCA2patients.
Authors: E Houben; H G M van Haalen; W Sparreboom; J A Overbeek; N P M Ezendam; J M A Pijnenborg; J L Severens; M P P van Herk-Sukel Journal: Med Oncol Date: 2017-02-21 Impact factor: 3.064
Authors: Marline G Harmsen; Marieke Arts-de Jong; Nicoline Hoogerbrugge; Angela H E M Maas; Judith B Prins; Johan Bulten; Steven Teerenstra; Eddy M M Adang; Jurgen M J Piek; Helena C van Doorn; Marc van Beurden; Marian J E Mourits; Ronald P Zweemer; Katja N Gaarenstroom; Brigitte F M Slangen; M Caroline Vos; Luc R C W van Lonkhuijzen; Leon F A G Massuger; Rosella P M G Hermens; Joanne A de Hullu Journal: BMC Cancer Date: 2015-08-19 Impact factor: 4.430
Authors: Wiktor Szatkowski; Paweł Blecharz; Jerzy W Mituś; Marek Jasiówka; Elżbieta Łuczyńska; Jerzy Jakubowicz; Tomasz Byrski Journal: Hered Cancer Clin Pract Date: 2016-01-23 Impact factor: 2.857
Authors: Ingrid Slade; Helen Hanson; Angela George; Kelly Kohut; Ann Strydom; Sarah Wordsworth; Nazneen Rahman Journal: J Community Genet Date: 2016-02-27
Authors: Bernadette A M Heemskerk-Gerritsen; Antoinette Hollestelle; Christi J van Asperen; Irma van den Beek; Willemien J van Driel; Klaartje van Engelen; Encarna B Gómez Garcia; Joanne A de Hullu; Marco J Koudijs; Marian J E Mourits; Maartje J Hooning; Ingrid A Boere Journal: PLoS One Date: 2022-09-22 Impact factor: 3.752
Authors: Leendert H Zaaijer; Helena C van Doorn; Marian J E Mourits; Marc van Beurden; Joanne A de Hullu; Muriel A Adank; Luc R C W van Lonkhuijzen; Hans F A Vasen; Brigitte F M Slangen; Katja N Gaarenstroom; Ronald P Zweemer; Peggy M L H Vencken; Caroline Seynaeve; Mieke Kriege Journal: Br J Cancer Date: 2016-10-18 Impact factor: 7.640